Galderma has raised its full-year 2026 guidance following a strong first-half performance, with RBC Capital Markets upgrading the company's outlook and citing robust execution across its integrated aesthetics and pharmaceutical portfolio. The upgrade reflects sustained demand for Restylane fillers, Sculptra biostimulator, and Dysport toxin, alongside successful launches in emerging markets including India.
Business & M&A
Galderma Raises 2026 Guidance After Robust H1
RBC upgrades outlook as integrated aesthetics and pharma model accelerates.
Galderma raises 2026 guidance after strong H1 results.
Galderma's integrated model—combining aesthetics injectables, energy devices (via partnerships), and dermatological pharmaceuticals—continues to differentiate it from pure-play toxin and filler competitors. For practices, Galderma's momentum signals confidence in filler and biostimulator demand and suggests stable supply and pricing through 2026. Berenberg analysts have also backed the model, reinforcing institutional conviction in the company's competitive positioning.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.